LONARDI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.489
AS - Asia 200
EU - Europa 196
SA - Sud America 1
Totale 2.886
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.487
CN - Cina 189
IT - Italia 65
DE - Germania 37
FI - Finlandia 33
GB - Regno Unito 24
SE - Svezia 19
UA - Ucraina 11
IN - India 5
CA - Canada 2
FR - Francia 2
IR - Iran 2
NL - Olanda 2
TR - Turchia 2
AR - Argentina 1
BG - Bulgaria 1
HK - Hong Kong 1
IE - Irlanda 1
MK - Macedonia 1
SY - Repubblica araba siriana 1
Totale 2.886
Salva come PNG Salva come JPEG
Città #
Fairfield 463
Chandler 346
Ashburn 196
Seattle 190
Cambridge 174
Woodbridge 174
Houston 167
Ann Arbor 128
Wilmington 125
Beijing 55
San Diego 49
Medford 43
Princeton 43
Helsinki 29
Des Moines 27
Padova 27
Guangzhou 18
Roxbury 17
Jacksonville 12
Boardman 11
Los Angeles 9
Nanjing 8
New York 8
London 7
Nanchang 7
Changsha 6
Hefei 6
Jinan 6
Falls Church 5
Shenyang 5
Alassio 4
Hebei 4
Kharkiv 4
Kilburn 4
Kunming 4
Ningbo 4
Shanghai 4
New Bedfont 3
Ogden 3
Prescot 3
Pune 3
Taizhou 3
Tappahannock 3
Ankara 2
Chengdu 2
Chicago 2
Chongqing 2
Giugliano In Campania 2
Hangzhou 2
Hanover 2
Jiaxing 2
Lanzhou 2
Lappeenranta 2
Menlo Park 2
Norwalk 2
Nürnberg 2
Soemmerda 2
Tehran 2
Terni 2
Trento 2
Treviso 2
Vicenza 2
Vicopisano 2
Xian 2
Zhengzhou 2
Bologna 1
Borås 1
Castelfranco Veneto 1
Cesena 1
Dearborn 1
Dolo 1
Dublin 1
Elk Grove Village 1
Erding 1
Falkenstein 1
Haikou 1
Hounslow 1
Indiana 1
Jose Maria Ezeiza 1
Latham 1
Milan 1
Modena 1
Monmouth Junction 1
Nanning 1
North Wales 1
Phoenix 1
Pinerolo 1
Quzhou 1
Redwood City 1
Romford 1
San Francisco 1
Sofia 1
Stefania 1
Stockholm 1
Tianjin 1
Toronto 1
Trieste 1
Verona 1
Washington 1
Wenzhou 1
Totale 2.486
Salva come PNG Salva come JPEG
Nome #
Class 1, 2 and 3 BRAF mutated metastatic colorectal cancer: a detailed clinical, pathological and molecular characterization 164
The predictive and prognostic potential of plasma telomerase reverse transcriptase (TERT) RNA in rectal cancer patients 132
BRAF p.V600E-specific immunohistochemical assessment in colorectal cancer endoscopy biopsies is consistent with the mutational profiling 130
An overview on clinical, pathological and molecular features of lung metastases from colorectal cancer 125
CK7 and consensus molecular subtypes as major prognosticators in V600E BRAF mutated metastatic colorectal cancer 123
Immunotherapy in Gastrointestinal Cancers 118
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden 115
miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis 111
Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study 110
Immunotherapy in Gastrointestinal Cancers 107
Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases 104
The INTERACT Trial: Long-term results of a randomised trial on preoperative capecitabine-based radiochemotherapy intensified by concomitant boost or oxaliplatin, for cT2 (distal)–cT3 rectal cancer 97
Pathological Tumor Regression Grade Classifications in Gastrointestinal Cancers: Role on Patients’ Prognosis 97
PD-L1 expression in gastroesophageal dysplastic lesions 90
An untreatable dyspnoea: more defendants under investigation 86
Transarterial Chemoembolization with Small Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: Experience from a Cohort of 421 Patients at an Italian Center 76
Another Chapter of the Right Versus Left Story: Is Primary Tumor Location a Prognostic Feature in RAS Mutant Metastatic Colorectal Cancer? 71
The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer 63
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study 60
MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors 60
Outcome of patients with colorectal cancer undergoing lung metastases resection: a single-institution retrospective analysis 57
Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives 56
Lymph node ratio is a powerful prognostic factor in patients receiving preoperative chemoradiotherapy for rectal cancer. 55
Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial 54
Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis 53
Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab 52
Non-Operative Management Versus Total Mesorectal Excision for Locally Advanced Rectal Cancer with Clinical Complete Response After Neoadjuvant Chemoradiotherapy: a GRADE Approach by the Rectal Cancer Guidelines Writing Group of the Italian Association of Medical Oncology (AIOM) 46
Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes 45
Modulation of preoperative chemoradiation can reduce the requirement for abdomino-perineal resection in low rectal cancer patients 42
PD-L1 and Notch as novel biomarkers in pancreatic sarcomatoid carcinoma: a pilot study 35
A real-world application of liquid biopsy in metastatic colorectal cancer: The poseidon study 33
Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: The CARACAS study 29
Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer 28
BRAF-mutated colorectal adenocarcinomas: pathological heterogeneity and clinical implications 26
Proposta di PDTA per i pazienti affetti da tumore del pancreas 25
Ramucirumab: the long and winding road toward being an option for mCRC treatment 25
MMR profile and microsatellite instability status in colorectal mucinous adenocarcinoma with synchronous metastasis: a new clue for the clinical practice 25
Microsatellite Instable Colorectal Adenocarcinoma Diagnostics: The Advent of Liquid Biopsy Approaches 21
Negative Ultraselection of Patients with RAS / BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti-EGFR-Based Therapy 21
Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020-Sep 2020; Sep 2020-May 2021) in the Veneto Oncology Network: The ROVID study 20
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter? 19
Mismatch repair status and gastro-oesophageal dysplasia: need for a dedicated gastrointestinal pathologist? 19
Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter 18
Multimodal treatment of radiation-induced esophageal cancer: Results of a case-matched comparative study from a single center 17
Case report: Complete pathologic response with first-line immunotherapy combination in a young adult with massive liver dissemination of mismatch repair-deficient metastatic colorectal cancer: Immunological and molecular profiling 16
Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma 15
null 15
Impact of Positive Radial Margin on Recurrence and Survival in Perihilar Cholangiocarcinoma 11
Claudin-18 expression in small bowel adenocarcinoma: a clinico-pathologic study 11
Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas 11
HER2-CDH1 Interaction via Wnt/B-Catenin Is Associated with Patients' Survival in HER2-Positive Metastatic Gastric Adenocarcinoma 7
To resect or not to resect?-the dilemma in oligometastatic breast cancer 3
Platinum sensitivity in patients with IDH1/2 mutated versus wild-type intrahepatic cholangiocarcinoma: a propensity score-based study 1
Totale 2.950
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.305
article - articoli 13.896
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.201
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019125 0 0 0 0 0 0 0 0 0 0 53 72
2019/2020748 47 31 24 155 52 41 94 76 85 50 39 54
2020/2021517 23 120 18 34 10 51 17 63 53 70 38 20
2021/2022572 28 64 46 36 32 29 61 42 48 13 43 130
2022/2023614 92 82 11 95 78 68 12 49 77 10 33 7
2023/2024286 11 64 37 21 22 56 44 3 13 14 1 0
Totale 2.950